Dr. Doody and colleagues reply

New England Journal of Medicine

Volumn 370, Issue 15, 2014, Pages 1460-

  Doody, Rachelle S ^a   Farlow, Martin ^b   Aisen, Paul S ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; PLACEBO; SOLANEZUMAB; AMYLOID BETA PROTEIN; MONOCLONAL ANTIBODY;

ALZHEIMER DISEASE; BRAIN LEVEL; CLINICAL TRIAL (TOPIC); COGNITION; DISEASE SEVERITY; DRUG EFFICACY; FUNCTIONAL ASSESSMENT; GENE MUTATION; HIGH RISK POPULATION; HUMAN; LETTER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; DRUG ANTAGONISM; FEMALE; MALE; NOTE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; MALE;

EID: 84898887456     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1402193     Document Type: Letter

References (7)

1. S Salloway R Sperling NC Fox Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease N Engl J Med 370 2014 322 333
2. RS Doody RG Thomas M Farlow Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease N Engl J Med 370 2014 311 321
3. HW Querfurth FM LaFerla Alzheimer's disease N Engl J Med 362 2010 329 344
4. E Karran J Hardy Antiamyloid therapy for Alzheimer's disease — are we on the right road? N Engl J Med 370 2014 377 378
5. JC de la Torre Vascular risk factors: a ticking time bomb to Alzheimer's disease Am J Alzheimers Dis Other Demen 28 2013 551 559
6. RS Doody RG Thomas M Farlow Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease N Engl J Med 370 2014 311 321
7. LE Hebert LA Beckett PA Scherr DA Evans Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050 Alzheimer Dis Assoc Disord 15 2001 169 173